Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 4 | Immunity & Ageing

Fig. 4

From: Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults

Fig. 4

Summary of RSV/A and RSV/B Microneutralization Responses. RSV/A (a) and RSV/B (b) microneutralization antibody response kinetics in active vaccine and placebo recipients co-administered TIV based on the fold-rise in post-vaccination GMTs relative to baseline (GMRPost/Pre). Data are represented by the GMT and associated 95% CIs. The pooled day 0 GMT was log2 8.2 or GMT 294 (258–334 95% CI) for RSV/A MN and log2 8.1 or GMT 284 (239–336, 95% CI) for RSV/B MN

Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us